Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD Study of Marstacimab in Healthy Volunteers
NCT02531815Phase 1Completed
- Sponsor
- Pfizer
- Start
- Aug 2015
- Primary completion
- Jul 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of marstacimab in hemophilia A and hemophilia B (HB) (8 cohorts), sponsored by Pfizer. Primary endpoints: Treatment Emergent Adverse Events, Percentage of subjects with laboratory abnormalities and 5 more. Started Aug 2015; status: completed.
02
Drugs
marstacimab
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on NCT02531815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02531815.